Challenges and lessons learned in conducting comparative-effectiveness trials

American Journal of Gastroenterology

Volumn 107, Issue 5, 2012, Pages 644-649

  Herrick, Linda M ^a,b   Locke III, G Richard ^a   Zinsmeister, Alan R ^a   Talley, Nicholas J ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ESCITALOPRAM; PLACEBO;

BUDGET; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DYSPEPSIA; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL INFORMATION; MULTICENTER STUDY (TOPIC); PARTICIPATORY MANAGEMENT; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TEAM BUILDING; TECHNOLOGY; UNSPECIFIED SIDE EFFECT; ARTICLE; EVIDENCE BASED MEDICINE; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PERSONNEL; PUBLISHING;

COMPARATIVE EFFECTIVENESS RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH PERSONNEL; TECHNOLOGY TRANSFER;

EID: 84862305307     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.475     Document Type: Review

References (13)

1. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. National Academies Press: Washington, DC, 2009.
2. National Institute of Diabetes and Digestive and Kidney Diseases. Cooperative Agreement Terms and Conditions of Award. NIDDK Multi-Center Clinical Study Cooperative Agreement (U01). Program Announcement PAR-08-058, section VI.2 〈http://grants.nih.gov/grants/guide/pa-files/PAR-08-058. html#SectionVI2〉 (2007).
3. Agency for Healthcare Research and Quality. US Food and Drug Administration. Comparative effectiveness 101. 4th Annual FDA/DIA Statistics Forum, Bethesda, MD, 21 April 2010.
4. Domanski D, McKinlay S. Successful Randomized Trials. Lippincott Williams & Wilkins: Philadelphia, PA, 2009.
5. Talley NJ, Locke GR, Herrick LM et al. Functional Dyspepsia Treatment Trial (FDTT): A double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials 2012:33:523-533.
6. National Institute of Diabetes and Digestive and Kidney Diseases. New Study Examines Brain-Gut Relationship in Those Suffering with Stomach Pain or Discomfort (Functional Dyspepsia). NIH News, 5 September 2007 〈http://www.nih.gov/news/pr/sep2007/niddk-05.htm〉.
7. National Institute of Diabetes and Digestive and Kidney Diseases. NIDDK Multi-Center Clinical Study Cooperative Agreement (U01). Program Announcement PAR-08-058 〈http://grants.nih.gov/grants/guide/pa-files/PAR-08-058. html〉 (2007).
8. McPhaul MJ, Toto RD. Clinical Research: From Proposal to Implementation. Lippincott Williams & Wilkins: Philadelphia, PA, 2011.
9. Talley NJ, Zinsmeister AR, Schleck CD et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-68.
10. Choung RS, Locke GR, Schleck CD et al. Do distinct dyspepsia subgroups exist in the community? A population-based study. Am J Gastroenterol 2007;102:1983-9. (Pubitemid 47301535)
11. US Food and Drug Administration. Investigational New Drug Application 〈http://www.fda.gov/drugs/developmentapprovalprocess/ howdrugsaredevelopedandapproved/approvalapplications/ investigationalnewdrugindapplication/default.htm〉.
12. Holbrook JT, Kempen JH, Prusakowski NA et al. Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial - lessons for comparative effectiveness trials. Clin Trials 2011;8:736-43.
13. Therneau T. How many stratification factors are "too many" to use in a randomization plan? Control Clin Trials 1993;14:98-108. (Pubitemid 23102299)